{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T20:14:46Z","timestamp":1793650486443,"version":"4.5.1"},"reference-count":122,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.1016\/j.blre.2010.10.004","type":"journal-article","created":{"date-parts":[[2010,11,21]],"date-time":"2010-11-21T09:11:43Z","timestamp":1290330703000},"page":"53-63","source":"Crossref","is-referenced-by-count":61,"title":["JAK2 inhibitors: What's the true therapeutic potential?"],"prefix":"10.1016","volume":"25","author":[{"given":"Fabio P.S.","family":"Santos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srdan","family":"Verstovsek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.blre.2010.10.004_bb0005","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.beha.2005.07.001","article-title":"Classification of chronic myeloid disorders: from Dameshek towards a semi-molecular system","volume":"19","author":"Tefferi","year":"2006","journal-title":"Best Pract Res Clin Haematol"},{"issue":"17","key":"10.1016\/j.blre.2010.10.004_bb0010","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1056\/NEJM200004273421706","article-title":"Myelofibrosis with myeloid metaplasia","volume":"342","author":"Tefferi","year":"2000","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.blre.2010.10.004_bb0015","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/(SICI)1096-8652(199905)61:1<10::AID-AJH3>3.0.CO;2-I","article-title":"Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County Study, 1976\u20131995","volume":"61","author":"Mesa","year":"1999","journal-title":"Am J Hematol"},{"issue":"8","key":"10.1016\/j.blre.2010.10.004_bb0020","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1038\/leu.2008.177","article-title":"Evidence and expertise in the management of polycythemia vera and essential thrombocythemia","volume":"22","author":"Finazzi","year":"2008","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.blre.2010.10.004_bb0025","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1182\/blood-2004-09-3426","article-title":"Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study","volume":"105","author":"Finazzi","year":"2005","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2010.10.004_bb0030","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa043800","article-title":"Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia","volume":"353","author":"Harrison","year":"2005","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.blre.2010.10.004_bb0035","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1182\/blood-2009-07-235119","article-title":"Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasms","volume":"115","author":"Thoennissen","year":"2010","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.blre.2010.10.004_bb0040","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.beha.2005.07.008","article-title":"Myelofibrosis with myeloid metaplasia: disease overview and non-transplant treatment options","volume":"19","author":"Mesa","year":"2006","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.blre.2010.10.004_bb0045","doi-asserted-by":"crossref","DOI":"10.1007\/s00277-010-1019-9","article-title":"Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients","author":"Martinez-Trillos","year":"2010","journal-title":"Ann Hematol"},{"issue":"7","key":"10.1016\/j.blre.2010.10.004_bb0050","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1182\/blood-2002-09-2928","article-title":"A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia","volume":"101","author":"Mesa","year":"2003","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.blre.2010.10.004_bb0055","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.4971.4971","article-title":"Hydroxyurea effect on marked splenomegaly associated with primary myelofibrosis: response rates and correlation with JAK2V617F allele burden [abstract]","volume":"114","author":"Siragusa","year":"2009","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2010.10.004_bb0060","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/cncr.22021","article-title":"Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic","volume":"107","author":"Mesa","year":"2006","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.blre.2010.10.004_bb0065","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/cncr.22365","article-title":"The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients","volume":"109","author":"Mesa","year":"2007","journal-title":"Cancer"},{"issue":"9464","key":"10.1016\/j.blre.2010.10.004_bb0070","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"issue":"7037","key":"10.1016\/j.blre.2010.10.004_bb0075","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"issue":"17","key":"10.1016\/j.blre.2010.10.004_bb0080","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.blre.2010.10.004_bb0085","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.blre.2010.10.004_bb0090","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1073\/pnas.86.5.1603","article-title":"Two putative protein-tyrosine kinases identified by application of the polymerase chain reaction","volume":"86","author":"Wilks","year":"1989","journal-title":"Proc Natl Acad Sci USA"},{"issue":"9","key":"10.1016\/j.blre.2010.10.004_bb0095","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1093\/protein\/15.9.727","article-title":"Prediction of the structure of human Janus kinase 2 (JAK2) comprising JAK homology domains 1 through 7","volume":"15","author":"Giordanetto","year":"2002","journal-title":"Protein Eng"},{"issue":"4","key":"10.1016\/j.blre.2010.10.004_bb0100","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1128\/MCB.11.4.2057","article-title":"Two novel protein-tyrosine kinases, each with a second phosphotransferase-related catalytic domain, define a new class of protein kinase","volume":"11","author":"Wilks","year":"1991","journal-title":"Mol Cell Biol"},{"issue":"49","key":"10.1016\/j.blre.2010.10.004_bb0105","doi-asserted-by":"crossref","first-page":"47954","DOI":"10.1074\/jbc.M205156200","article-title":"The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction","volume":"277","author":"Saharinen","year":"2002","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.blre.2010.10.004_bb0110","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/protein\/14.1.27","article-title":"Prediction of the structure of human Janus kinase 2 (JAK2) comprising the two carboxy-terminal domains reveals a mechanism for autoregulation","volume":"14","author":"Lindauer","year":"2001","journal-title":"Protein Eng"},{"issue":"27","key":"10.1016\/j.blre.2010.10.004_bb0115","doi-asserted-by":"crossref","first-page":"25760","DOI":"10.1074\/jbc.M500822200","article-title":"The Jak1 SH2 domain does not fulfill a classical SH2 function in Jak\/STAT signaling but plays a structural role for receptor interaction and up-regulation of receptor surface expression","volume":"280","author":"Radtke","year":"2005","journal-title":"J Biol Chem"},{"issue":"6","key":"10.1016\/j.blre.2010.10.004_bb0120","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/S1097-2765(01)00401-4","article-title":"The N-terminal domain of Janus kinase 2 is required for Golgi processing and cell surface expression of erythropoietin receptor","volume":"8","author":"Huang","year":"2001","journal-title":"Mol Cell"},{"issue":"29","key":"10.1016\/j.blre.2010.10.004_bb0125","doi-asserted-by":"crossref","first-page":"27251","DOI":"10.1074\/jbc.M501376200","article-title":"Janus kinases affect thrombopoietin receptor cell surface localization and stability","volume":"280","author":"Royer","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.blre.2010.10.004_bb0130","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1146\/annurev.immunol.16.1.293","article-title":"Jaks and STATs: biological implications","volume":"16","author":"Leonard","year":"1998","journal-title":"Annu Rev Immunol"},{"issue":"2","key":"10.1016\/j.blre.2010.10.004_bb0135","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nrc1275","article-title":"The STATs of cancer \u2014 new molecular targets come of age","volume":"4","author":"Yu","year":"2004","journal-title":"Nat Rev Cancer"},{"issue":"52","key":"10.1016\/j.blre.2010.10.004_bb0140","doi-asserted-by":"crossref","first-page":"30837","DOI":"10.1074\/jbc.270.52.30837","article-title":"JAK2, Ras, and Raf are required for activation of extracellular signal-regulated kinase\/mitogen-activated protein kinase by growth hormone","volume":"270","author":"Winston","year":"1995","journal-title":"J Biol Chem"},{"issue":"5","key":"10.1016\/j.blre.2010.10.004_bb0145","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1349-7006.2000.tb00977.x","article-title":"Ras and signal transducer and activator of transcription (STAT) are essential and sufficient downstream components of Janus kinases in cell proliferation","volume":"91","author":"Mizuguchi","year":"2000","journal-title":"Jpn J Cancer Res"},{"issue":"9","key":"10.1016\/j.blre.2010.10.004_bb0150","doi-asserted-by":"crossref","first-page":"5333","DOI":"10.1074\/jbc.274.9.5333","article-title":"Granulocyte-macrophage colony-stimulating factor-activated signaling pathways in human neutrophils. Involvement of Jak2 in the stimulation of phosphatidylinositol 3-kinase","volume":"274","author":"Al-Shami","year":"1999","journal-title":"J Biol Chem"},{"issue":"9","key":"10.1016\/j.blre.2010.10.004_bb0155","doi-asserted-by":"crossref","first-page":"3436","DOI":"10.1182\/blood-2002-07-2332","article-title":"Critical role for PI 3-kinase in the control of erythropoietin-induced erythroid progenitor proliferation","volume":"101","author":"Bouscary","year":"2003","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.blre.2010.10.004_bb0160","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/0092-8674(95)90351-8","article-title":"Specific recruitment of SH-PTP1 to the erythropoietin receptor causes inactivation of JAK2 and termination of proliferative signals","volume":"80","author":"Klingmuller","year":"1995","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.blre.2010.10.004_bb0165","doi-asserted-by":"crossref","first-page":"3845","DOI":"10.1073\/pnas.95.7.3845","article-title":"Recruitment of SH2-containing protein tyrosine phosphatase SHP-1 to the interleukin 2 receptor; loss of SHP-1 expression in human T-lymphotropic virus type I-transformed T cells","volume":"95","author":"Migone","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6818","key":"10.1016\/j.blre.2010.10.004_bb0170","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/35053086","article-title":"CD45 is a JAK phosphatase and negatively regulates cytokine receptor signalling","volume":"409","author":"Irie-Sasaki","year":"2001","journal-title":"Nature"},{"issue":"6636","key":"10.1016\/j.blre.2010.10.004_bb0175","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1038\/43213","article-title":"A new protein containing an SH2 domain that inhibits JAK kinases","volume":"387","author":"Endo","year":"1997","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.blre.2010.10.004_bb0180","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1128\/MCB.22.10.3316-3326.2002","article-title":"Regulation of Jak2 through the ubiquitin-proteasome pathway involves phosphorylation of Jak2 on Y1007 and interaction with SOCS-1","volume":"22","author":"Ungureanu","year":"2002","journal-title":"Mol Cell Biol"},{"issue":"3","key":"10.1016\/j.blre.2010.10.004_bb0185","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S0092-8674(00)81166-6","article-title":"Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses","volume":"93","author":"Rodig","year":"1998","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.blre.2010.10.004_bb0190","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0092-8674(00)81167-8","article-title":"Jak2 is essential for signaling through a variety of cytokine receptors","volume":"93","author":"Parganas","year":"1998","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.blre.2010.10.004_bb0195","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0092-8674(00)81168-X","article-title":"Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis","volume":"93","author":"Neubauer","year":"1998","journal-title":"Cell"},{"issue":"5237","key":"10.1016\/j.blre.2010.10.004_bb0200","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1126\/science.270.5237.800","article-title":"Defective lymphoid development in mice lacking Jak3","volume":"270","author":"Nosaka","year":"1995","journal-title":"Science"},{"issue":"5237","key":"10.1016\/j.blre.2010.10.004_bb0205","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1126\/science.270.5237.794","article-title":"Defects in B lymphocyte maturation and T lymphocyte activation in mice lacking Jak3","volume":"270","author":"Thomis","year":"1995","journal-title":"Science"},{"issue":"6544","key":"10.1016\/j.blre.2010.10.004_bb0210","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/377065a0","article-title":"Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID)","volume":"377","author":"Macchi","year":"1995","journal-title":"Nature"},{"issue":"5237","key":"10.1016\/j.blre.2010.10.004_bb0215","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1126\/science.270.5237.797","article-title":"Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development","volume":"270","author":"Russell","year":"1995","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.blre.2010.10.004_bb0220","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S1074-7613(00)00054-6","article-title":"Partial impairment of cytokine responses in Tyk2-deficient mice","volume":"13","author":"Karaghiosoff","year":"2000","journal-title":"Immunity"},{"issue":"4","key":"10.1016\/j.blre.2010.10.004_bb0225","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S1074-7613(00)00055-8","article-title":"Tyk2 plays a restricted role in IFN alpha signaling, although it is required for IL-12-mediated T cell function","volume":"13","author":"Shimoda","year":"2000","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.blre.2010.10.004_bb0230","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1128\/MCB.17.3.1562","article-title":"Mutation in the Jak kinase JH2 domain hyperactivates Drosophila and mammalian Jak\u2013Stat pathways","volume":"17","author":"Luo","year":"1997","journal-title":"Mol Cell Biol"},{"issue":"10","key":"10.1016\/j.blre.2010.10.004_bb0235","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1182\/blood-2005-05-1800","article-title":"JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia","volume":"106","author":"Jelinek","year":"2005","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.blre.2010.10.004_bb0240","doi-asserted-by":"crossref","first-page":"4922","DOI":"10.1182\/blood-2007-11-125328","article-title":"The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases","volume":"111","author":"Kiladjian","year":"2008","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.blre.2010.10.004_bb0245","doi-asserted-by":"crossref","first-page":"5246","DOI":"10.1182\/blood-2008-11-191544","article-title":"The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd\u2013Chiari syndrome","volume":"113","author":"Sozer","year":"2009","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.blre.2010.10.004_bb0250","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/ng.341","article-title":"A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms","volume":"41","author":"Olcaydu","year":"2009","journal-title":"Nat Genet"},{"issue":"4","key":"10.1016\/j.blre.2010.10.004_bb0255","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/ng.342","article-title":"A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms","volume":"41","author":"Kilpivaara","year":"2009","journal-title":"Nat Genet"},{"issue":"4","key":"10.1016\/j.blre.2010.10.004_bb0260","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/ng.334","article-title":"JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms","volume":"41","author":"Jones","year":"2009","journal-title":"Nat Genet"},{"issue":"6","key":"10.1016\/j.blre.2010.10.004_bb0265","doi-asserted-by":"crossref","first-page":"e11157","DOI":"10.1371\/journal.pone.0011157","article-title":"JAK2 V617F constitutive activation requires JH2 residue F595: a pseudokinase domain target for specific inhibitors","volume":"5","author":"Dusa","year":"2010","journal-title":"PLoS ONE"},{"issue":"5","key":"10.1016\/j.blre.2010.10.004_bb0270","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1182\/blood-2006-02-002030","article-title":"JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis","volume":"108","author":"Lacout","year":"2006","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.blre.2010.10.004_bb0275","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.1182\/blood-2005-12-4824","article-title":"Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model","volume":"107","author":"Wernig","year":"2006","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.blre.2010.10.004_bb0280","doi-asserted-by":"crossref","first-page":"11156","DOI":"10.1158\/0008-5472.CAN-06-2210","article-title":"Characterization of murine JAK2V617F-positive myeloproliferative disease","volume":"66","author":"Bumm","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.blre.2010.10.004_bb0285","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1371\/journal.pone.0000018","article-title":"Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F","volume":"1","author":"Zaleskas","year":"2006","journal-title":"PLoS ONE"},{"issue":"10","key":"10.1016\/j.blre.2010.10.004_bb0290","doi-asserted-by":"crossref","first-page":"5109","DOI":"10.1182\/blood-2007-05-091579","article-title":"Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice","volume":"111","author":"Xing","year":"2008","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.blre.2010.10.004_bb0295","doi-asserted-by":"crossref","first-page":"3931","DOI":"10.1182\/blood-2007-08-107748","article-title":"Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice","volume":"111","author":"Tiedt","year":"2008","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2010.10.004_bb0300","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/sj.leu.2405043","article-title":"Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F","volume":"22","author":"Shide","year":"2008","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.blre.2010.10.004_bb0305","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.ccr.2010.05.015","article-title":"Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells","volume":"17","author":"Mullally","year":"2010","journal-title":"Cancer Cell"},{"issue":"17","key":"10.1016\/j.blre.2010.10.004_bb0310","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1182\/blood-2009-04-215848","article-title":"Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease","volume":"115","author":"Akada","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.blre.2010.10.004_bb0315","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2009-12-259747","article-title":"JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia","author":"Li","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.blre.2010.10.004_bb0320","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2009-12-257063","article-title":"Myeloproliferative neoplasm induced by constitutive expression of JAK2V617F in knock-in mice","author":"Marty","year":"2010","journal-title":"Blood"},{"issue":"7265","key":"10.1016\/j.blre.2010.10.004_bb0325","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1038\/nature08448","article-title":"JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin","volume":"461","author":"Dawson","year":"2009","journal-title":"Nature"},{"issue":"16","key":"10.1016\/j.blre.2010.10.004_bb0330","doi-asserted-by":"crossref","first-page":"6224","DOI":"10.1073\/pnas.0601462103","article-title":"The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation","volume":"103","author":"Jamieson","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"10.1016\/j.blre.2010.10.004_bb0335","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1182\/blood-2005-03-1320","article-title":"Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders","volume":"106","author":"Jones","year":"2005","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.blre.2010.10.004_bb0340","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1182\/blood-2006-04-018259","article-title":"Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia","volume":"108","author":"Scott","year":"2006","journal-title":"Blood"},{"issue":"9501","key":"10.1016\/j.blre.2010.10.004_bb0345","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/S0140-6736(05)67785-9","article-title":"Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study","volume":"366","author":"Campbell","year":"2005","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.blre.2010.10.004_bb0350","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/j.1365-2141.2005.05764.x","article-title":"JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance","volume":"131","author":"Wolanskyj","year":"2005","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.blre.2010.10.004_bb0355","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1182\/blood-2006-12-064287","article-title":"Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia","volume":"110","author":"Vannucchi","year":"2007","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.blre.2010.10.004_bb0360","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/cncr.21645","article-title":"The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera","volume":"106","author":"Tefferi","year":"2006","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.blre.2010.10.004_bb0365","doi-asserted-by":"crossref","first-page":"4030","DOI":"10.1182\/blood-2007-07-099184","article-title":"JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis","volume":"110","author":"Barosi","year":"2007","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.blre.2010.10.004_bb0370","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1182\/blood-2009-04-216044","article-title":"Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele","volume":"114","author":"Guglielmelli","year":"2009","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.blre.2010.10.004_bb0375","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/sj.leu.2405097","article-title":"Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival","volume":"22","author":"Tefferi","year":"2008","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.blre.2010.10.004_bb0380","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa065202","article-title":"JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis","volume":"356","author":"Scott","year":"2007","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.blre.2010.10.004_bb0385","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1371\/journal.pmed.0030270","article-title":"MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia","volume":"3","author":"Pikman","year":"2006","journal-title":"PLoS Med"},{"issue":"1","key":"10.1016\/j.blre.2010.10.004_bb0390","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1182\/blood-2008-01-131664","article-title":"MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort","volume":"112","author":"Beer","year":"2008","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.blre.2010.10.004_bb0395","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1038\/leu.2008.137","article-title":"New mutations of MPL in primitive myelofibrosis: only the MPL W515 mutations promote a G1\/S-phase transition","volume":"22","author":"Chaligne","year":"2008","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.blre.2010.10.004_bb0400","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1182\/blood-2007-07-101576","article-title":"Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders","volume":"111","author":"Pietra","year":"2008","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.blre.2010.10.004_bb0405","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1038\/sj.leu.2404810","article-title":"Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera","volume":"21","author":"Pardanani","year":"2007","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.blre.2010.10.004_bb0410","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1038\/sj.leu.2404971","article-title":"Two novel JAK2 exon 12 mutations in JAK2V617F-negative polycythaemia vera patients","volume":"22","author":"Butcher","year":"2008","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.blre.2010.10.004_bb0415","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood-2006-04-018879","article-title":"MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients","volume":"108","author":"Pardanani","year":"2006","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.blre.2010.10.004_bb0420","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1365-2141.2007.06565.x","article-title":"Anaemia characterises patients with myelofibrosis harbouring Mpl mutation","volume":"137","author":"Guglielmelli","year":"2007","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.blre.2010.10.004_bb0425","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1182\/blood-2008-01-135897","article-title":"Characteristics and clinical correlates of MPL 515W>L\/K mutation in essential thrombocythemia","volume":"112","author":"Vannucchi","year":"2008","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2010.10.004_bb0430","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.exphem.2006.11.012","article-title":"Polycythemia vera is not initiated by JAK2V617F mutation","volume":"35","author":"Nussenzveig","year":"2007","journal-title":"Exp Hematol"},{"issue":"6","key":"10.1016\/j.blre.2010.10.004_bb0435","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1038\/leu.2010.69","article-title":"Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1","volume":"24","author":"Tefferi","year":"2010","journal-title":"Leukemia"},{"issue":"22","key":"10.1016\/j.blre.2010.10.004_bb0440","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMoa0810069","article-title":"Mutation in TET2 in myeloid cancers","volume":"360","author":"Delhommeau","year":"2009","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.blre.2010.10.004_bb0445","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1182\/blood-2009-08-236596","article-title":"Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm","volume":"115","author":"Beer","year":"2010","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.blre.2010.10.004_bb0450","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1182\/blood-2009-09-245381","article-title":"Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms","volume":"115","author":"Schaub","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.blre.2010.10.004_bb0455","doi-asserted-by":"crossref","DOI":"10.1038\/nature09303","article-title":"Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification","author":"Ito","year":"2010","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.blre.2010.10.004_bb0460","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1182\/blood-2008-02-138230","article-title":"The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms","volume":"112","author":"Tam","year":"2008","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.blre.2010.10.004_bb0465","doi-asserted-by":"crossref","first-page":"5663","DOI":"10.1182\/blood-2007-04-083402","article-title":"Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2\/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders","volume":"111","author":"Hexner","year":"2008","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.blre.2010.10.004_bb0470","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1182\/blood-2009-04-214957","article-title":"Preclinical characterization of the selective JAK1\/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms","volume":"115","author":"Quintas-Cardama","year":"2010","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2010.10.004_bb0475","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1056\/NEJMra044389","article-title":"Tyrosine kinases as targets for cancer therapy","volume":"353","author":"Krause","year":"2005","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.blre.2010.10.004_bb0480","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","article-title":"Safety and Efficacy of JAK1 & JAK2 Inhibitor, INCB018424, in Myelofibrosis","volume":"363","author":"Verstovsek","year":"2010","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.blre.2010.10.004_bb0485","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1038\/leu.2008.233","article-title":"Genetic complexity of myeloproliferative neoplasms","volume":"22","author":"Kralovics","year":"2008","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.blre.2010.10.004_bb0490","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/j.leukres.2009.06.001","article-title":"How do JAK2-inhibitors work in myelofibrosis: an alternative hypothesis","volume":"33","author":"Vannucchi","year":"2009","journal-title":"Leuk Res"},{"issue":"4","key":"10.1016\/j.blre.2010.10.004_bb0495","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1182\/blood.V96.4.1342","article-title":"Pathologic interaction between megakaryocytes and polymorphonuclear leukocytes in myelofibrosis","volume":"96","author":"Schmitt","year":"2000","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.blre.2010.10.004_bb0500","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1182\/blood-2006-12-064626","article-title":"Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis","volume":"110","author":"Ciurea","year":"2007","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.blre.2010.10.004_bb0505","doi-asserted-by":"crossref","first-page":"951","DOI":"10.2353\/ajpath.2008.071030","article-title":"Bone morphogenetic proteins are overexpressed in the bone marrow of primary myelofibrosis and are apparently induced by fibrogenic cytokines","volume":"172","author":"Bock","year":"2008","journal-title":"Am J Pathol"},{"issue":"1","key":"10.1016\/j.blre.2010.10.004_bb0510","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0002-9440(10)64511-7","article-title":"Bone marrow in polycythemia vera, chronic myelocytic leukemia, and myelofibrosis has an increased vascularity","volume":"157","author":"Lundberg","year":"2000","journal-title":"Am J Pathol"},{"issue":"11","key":"10.1016\/j.blre.2010.10.004_bb0515","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.2804.2804","article-title":"The clinical phenotype of myelofibrosis encompasses a chronic inflammatory state that is favorably altered by INCB018424, a selective inhibitor of JAK1\/2 [abstract].","volume":"112","author":"Tefferi","year":"2008","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2010.10.004_bb0520","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1182\/blood-2003-12-4415","article-title":"IL-8 and its CXCR1 and CXCR2 receptors participate in the control of megakaryocytic proliferation, differentiation, and ploidy in myeloid metaplasia with myelofibrosis","volume":"105","author":"Emadi","year":"2005","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.blre.2010.10.004_bb0525","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1038\/sj.leu.2400846","article-title":"Blood thrombopoietin, IL-6 and IL-11 levels in patients with agnogenic myeloid metaplasia","volume":"11","author":"Wang","year":"1997","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.blre.2010.10.004_bb0530","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1182\/blood-2008-09-176875","article-title":"Selective reduction of JAK2V617F-dependent cell growth by siRNA\/shRNA and its reversal by cytokines","volume":"114","author":"Jedidi","year":"2009","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.blre.2010.10.004_bb0535","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1182\/blood-2009-10-246363","article-title":"Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera\/essential thrombocythemia myelofibrosis","volume":"115","author":"Santos","year":"2010","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.blre.2010.10.004_bb0540","doi-asserted-by":"crossref","first-page":"3669","DOI":"10.1182\/blood-2003-11-3775","article-title":"Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia","volume":"103","author":"Smith","year":"2004","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.blre.2010.10.004_bb0545","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1182\/blood-2006-03-009746","article-title":"International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT)","volume":"108","author":"Tefferi","year":"2006","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.blre.2010.10.004_bb0550","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.754.754","article-title":"(Lestaurtinib) in adults with myelofibrosis; a report on phase I: a study of the Myeloproliferative Disorders Research Consortium (MPD-RC) [abstract]","volume":"114","author":"Hexner","year":"2009","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.blre.2010.10.004_bb0555","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.leukres.2009.01.035","article-title":"The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis","volume":"33","author":"Mesa","year":"2009","journal-title":"Leuk Res"},{"issue":"11","key":"10.1016\/j.blre.2010.10.004_bb0560","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V110.11.538.538","article-title":"SB1518: a potent and orally active JAK2 inhibitor for the treatment of myeloproliferative disorders [abstract]","volume":"110","author":"Goh","year":"2007","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.blre.2010.10.004_bb0565","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.3905.3905","article-title":"Phase I dose-escalation trial of SB1518, a novel JAK2\/FLT3 inhibitor, in acute and chronic myeloid diseases, including primary or post-essential thrombocythemia\/polycythemia vera myelofibrosis [abstract]","volume":"114","author":"Verstovsek","year":"2009","journal-title":"Blood"},{"issue":"suppl. 2","key":"10.1016\/j.blre.2010.10.004_bb0570","article-title":"First report of the phase I study of the novel oral JAK2 inhibitor SB1518 in patients with myelofibrosis [abstract]","volume":"95","author":"Seymour","year":"2010","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.blre.2010.10.004_bb0575","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.ccr.2008.02.017","article-title":"Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors","volume":"13","author":"Geron","year":"2008","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.blre.2010.10.004_bb0580","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ccr.2008.02.009","article-title":"Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera","volume":"13","author":"Wernig","year":"2008","journal-title":"Cancer Cell"},{"issue":"22","key":"10.1016\/j.blre.2010.10.004_bb0585","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.755.755","article-title":"A phase I evaluation of TG101348, a selective JAK2 inhibitor, in myelofibrosis: clinical response is accompanied by significant reduction in JAK2V617F allele burden [abstract]","volume":"114","author":"Pardanani","year":"2009","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.blre.2010.10.004_bb0590","article-title":"A phase I study of XL019, a selective JAK2 inhibitor, in patients with primary myelofibrosis and post-polycythemia vera\/essential thrombocythemia myelofibrosis [abstract]","volume":"110","author":"Verstovsek","year":"2007","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.blre.2010.10.004_bb0595","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.98.98","article-title":"A phase I study of XL019, a selective JAK2 inhibitor, in patients with primary myelofibrosis, post-polycythemia vera, or post-essential thrombocythemia myelofibrosis [abstract]","volume":"112","author":"Shah","year":"2008","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.blre.2010.10.004_bb0600","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.753.753","article-title":"An open-label study of CEP-701 in patients with JAK2 V617F-positive PV and ET: update of 39 enrolled patients [abstract]","volume":"114","author":"Moliterno","year":"2009","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.blre.2010.10.004_bb0605","article-title":"(PV) and essential thrombocythemia (ET) refractory to hydroxyurea [abstract]","volume":"114","author":"Verstovsek","year":"2009","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.blre.2010.10.004_bb0610","doi-asserted-by":"crossref","first-page":"4829","DOI":"10.1182\/blood-2008-09-176818","article-title":"Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference","volume":"113","author":"Barosi","year":"2009","journal-title":"Blood"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X10000603?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X10000603?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,14]],"date-time":"2020-06-14T00:26:53Z","timestamp":1592094413000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X10000603"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3]]},"references-count":122,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["S0268960X10000603"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2010.10.004","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2011,3]]}}}